跳至主要内容
临床试验/ISRCTN10942585
ISRCTN10942585
已完成
未知

Transcranial direct current stimulation (tDCS) as a therapeutic intervention for post-acute sequelae of SARS-CoV-2 (PASC)

Czech Health Research Council0 个研究点目标入组 33 人2022年5月6日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Post-acute sequelae of SARS-CoV-2 infection (PASC)
发起方
Czech Health Research Council
入组人数
33
状态
已完成
最后更新
2年前

概览

简要总结

2024 Results article in https://doi.org/10.1038/s41598-024-52763-4 (added 28/02/2024)

注册库
who.int
开始日期
2022年5月6日
结束日期
2023年12月31日
最后更新
2年前
研究类型
Interventional
性别
All

研究者

发起方
Czech Health Research Council

入排标准

入选标准

  • Current participant inclusion criteria as of 10/11/2023:
  • 1\. Male and female outpatients aged 18\-75 years with a history of COVID\-19 and monitored by an outpatient physician for mental disorders (anxiety, mood disorders, sleep) within the PASC
  • 2\. PCR RNA SARS\-CoV\-2 negativity at screening/study entry
  • 3\. Duration of symptoms \>1 and \=24 months after detection of COVID\-19
  • 4\. The mental ability to understand and sign the Informed Consent Form
  • 5\. Presence of neuropsychiatric PASC symptoms as determined by A\-PASC with a minimum overall score \=25 (cognitive score, emotional and functional impairment)
  • 6\. FIS questionnaire score \=40
  • 7\. Psychopharmacological medication (if used) at a stable dose \=4 weeks.
  • Previous participant inclusion criteria:
  • 1\. Male and female outpatients aged 18\-75 years with a history of COVID\-19 and monitored by an outpatient physician for mental disorders (anxiety, mood disorders, sleep) within the PASC

排除标准

  • 1\. Contraindications of tDCS (skin disease, superficial injury, and fracture or infraction of skull in the stimulation area, epilepsy, metallic plates in the head)
  • 2\. History of any other DSM\-IV axis I diagnosis prior to COVID\-19, except for:
  • 2\.1\. Depressive disorders, anxiety disorders, and sleep disorders that may be present in the history, but with at least 6 months of documented remission of symptoms
  • 2\.2\. Disorders associated with the use of addictive substances at least 6 months before entering the study
  • 3\. Pregnancy or breastfeeding
  • 4\. Patients with severe and/or unstable somatic disorders (cardiovascular disease, neoplasms, endocrinology disorders, etc)
  • 5\. Patients suffering from a serious neurological disorder (eg epilepsy, head injury with loss of consciousness)

结局指标

主要结局

未指定

相似试验